Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

HALO

HALOZYME THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1159036Held by 8 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$1.40B
Net Income FY2025
$0.32B
EPS (Basic, as reported)
$2.64
Net Margin FY2025
22.7%
ROE FY2025
649.2%
Total Equity
$0.05B
Shares Out
113M
Business description

HALOZYME THERAPEUTICS, INC. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 147 → 1,397 +28.4% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1473171521962684436608291,0151,397
Cost of revenue(33)(31)(10)(46)(43)(81)(139)(192)(159)(229)
Research & development(151)(151)(150)(141)(34)(36)(67)(76)(79)—
Selling, general & administrative(46)(54)(61)(77)(46)(50)(144)(149)(154)(207)
Total operating expenses(230)(236)(221)(264)(123)(167)(393)(492)(464)(928)
Operating income(83)81(69)(68)144276268338551469
Interest expense(20)(22)(18)(12)(20)(8)(17)(19)(18)(18)
Other income (expense), net1387511162421
Pre-tax income(102)62(80)(72)129249249348557467
Income tax expense(1)(1)(1)00(154)(47)(67)(113)(150)
Net income(103)63(80)(72)129403202282444317
EPS — basic($0.81)$0.46($0.56)($0.50)$0.95$2.86$1.48$2.13$3.50$2.64
EPS — diluted($0.81)$0.45($0.56)($0.50)$0.91$2.74$1.44$2.10$3.43$2.56
Shares outstanding — basic (M)128136144144136141137132127120
Shares outstanding — diluted (M)128139144144141147141134129124

Showing the latest 10 of 17 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.